# A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy

> **NCT03391479** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 25 (actual)

## Conditions studied

- Penile Cancer
- Advanced Cancer
- Metastatic Cancer

## Interventions

- **DRUG:** Avelumab
- **OTHER:** Best Supportive Care

## Key facts

- **NCT ID:** NCT03391479
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-08-15
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03391479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03391479, "A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT03391479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*